Hypoplastic acute myeloid leukemia with aberrant lymphoid antigen expression and EWSR1::FEV fusion: A rare case report and literature review
Therapeutic Advances in Hematology · 2026-08 · 17
DOI: 10.1177/20406207261481219 ↗Kurz gefasst
Fallbericht in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 19.08.2026. Verfasst von Wenxia Xia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, Guangdong, China. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Committee, Shenzhen Blood Center Scientific Research Project Fund.
Abstract (Originalsprache)
Ewing sarcoma breakpoint region 1 ( EWSR1 ):: Fifth Ewing variant ( FEV )-positive acute leukemia is exceptionally rare, and its clinicopathological features, molecular profile, and optimal treatment remain poorly defined. Here, we report a case of acute myeloid leukemia (AML) with bone marrow hypocellularity, aberrant lymphoid antigen expression, and an EWSR1::FEV fusion. A 45-year-old man was admitted with a 1-month history of petechiae and fatigue. Complete blood count (CBC) showed pancytopenia. Bone marrow (BM) examination revealed hypocellular marrow, with blasts accounting for 62% of nucleated cells. Flow cytometry (FCM) revealed a predominantly myeloid immunophenotype accompanied by aberrant expression of lymphoid-associated antigens. Conventional karyotyping did not identify a characteristic balanced translocation. Targeted next-generation sequencing (NGS) detected concurrent PTPN11 and NRAS mutations. RNA sequencing (RNA-seq) of the bone marrow sample identified the EWSR1::FEV fusion. Based on these findings, the patient was diagnosed with de novo AML with bone marrow hypocellularity and aberrant lymphoid antigen expression. Given the hypocellular marrow, venetoclax plus azacitidine (VA) was selected as induction therapy. The patient achieved morphological complete remission after one cycle, accompanied by a marked reduction in EWSR1::FEV transcript levels, and remained in morphological remission during approximately 6 months of follow-up after subsequent homoharringtonine combined with venetoclax plus azacitidine (HVA) consolidation. Together with previously reported cases, this case further supports the notion that EWSR1::FEV -positive acute leukemia may represent a distinct molecular subset characterized by lineage ambiguity, fusion-driven biology, and potentially unique therapeutic vulnerabilities. This case also suggests potential activity of venetoclax-based therapy in EWSR1::FEV -positive leukemia and warrants further investigation in additional cases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, Guangdong, China.
- Tianjin Union Precision Diagnosis Co., Ltd, Tianjin, China.
- Department of Hematology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
- Wuhan Kanglu Biomedical Co., Ltd, Wuhan, China.
ORCID-Profile: Jihao Zhou, Huijun Li, Junjie Hou
Förderung
- National Natural Science Foundation of China
- Shenzhen Science and Technology Innovation Committee
- Shenzhen Blood Center Scientific Research Project Fund
- Sanming Project of Medicine in Shenzen
Zitieren
APA
Xia, W., Zou, J., Chen, X., Luo, J., Feng, C., Dai, M., Ding, Y., Zhou, J., Ke, P., Li, H., & Hou, J. (2026). Hypoplastic acute myeloid leukemia with aberrant lymphoid antigen expression and EWSR1::FEV fusion: A rare case report and literature review. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261481219
Vancouver
Xia W, Zou J, Chen X, Luo J, Feng C, Dai M, et al. Hypoplastic acute myeloid leukemia with aberrant lymphoid antigen expression and EWSR1::FEV fusion: A rare case report and literature review. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261481219
BibTeX
@article{Xia2026,
author = {Xia, Wenxia and Zou, Junyan and Chen, Xiaoyong and Luo, Jing and Feng, Chun and Dai, Mao and Ding, Yanhong and Zhou, Jihao and Ke, Peng and Li, Huijun and Hou, Junjie},
title = {Hypoplastic acute myeloid leukemia with aberrant lymphoid antigen expression and EWSR1::FEV fusion: A rare case report and literature review},
journal = {Therapeutic Advances in Hematology},
year = {2026},
volume = {17},
doi = {10.1177/20406207261481219}
}
EUVIMED